

1 **Effects of nutritional supplements on antibody levels in pregnant**

2 **women vaccinated with inactivated SARS-CoV-2 vaccines**

3

4 **Short Title: Effects of nutritional supplements on antibody levels in pregnant**
5 **women**

6

7 Xi Zhang, MPH¹, Xue Han, MPH¹, Baolan Chen, MPH¹, Xi Fu, MD¹, Yajie Gong,
8 MD^{2,*}, Wenhan Yang, MD^{3,*}, Qingsong Chen, MD^{1,*}

9

10 ¹ Department of Occupational and Environmental Health, School of Public Health,
11 Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, 510006,
12 China

13 ² Department of Epidemiology and Medical Statistics, School of Public Health,
14 Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, 510006,
15 China

16 ³ Department of Child and Adolescent Health, School of Public Health, Guangdong
17 Pharmaceutical University, Guangzhou, Guangdong Province, 510006, China

18

19 ***Corresponding Author:**

20 1. Qingsong Chen, E-mail: qingsongchen@aliyun.com,

21 2. Wenhan Yang, E-mail: wenhan-yang@gdpu.edu.cn

22 3. Yajie Gong, E-mail: gongyajie2016@163.com

23

24

25

26

27

28

29 **Abstract**

30 **Background:** Because of the significantly higher demand for nutrients during
31 pregnancy, pregnant women are more likely to have nutrient deficiencies, which may
32 adversely affect maternal and fetal health. The effect of nutritional supplements on the
33 immune effects of inactivated SARS-CoV-2 vaccines during pregnancy is not clear.

34 **Methods:** In a multicenter cross-sectional study, we enrolled 873 pregnant women aged
35 18-45 y in Guangdong, China. The general demographic characteristics of pregnant
36 women and their use of nutritional supplements were investigated, and the serum
37 antibody levels induced by inactivated SARS-CoV-2 vaccines were measured. A
38 logistic regression model was used to analyze the association between nutritional
39 supplements and SARS-CoV-2 antibody levels.

40 **Results:** Of the 873 pregnant women enrolled, 825 (94.5%) took folic acid during
41 pregnancy, 165 (18.9%) took iron supplements, and 197 (22.6%) took DHA. All
42 pregnant women received at least one dose of inactivated SARS-CoV-2 vaccine, and
43 the positive rates of serum SARS-CoV-2 neutralizing antibodies (NAbs) and
44 immunoglobulin G (IgG) antibodies were 44.7% and 46.4%, respectively. After
45 adjustment for confounding factors, whether pregnant women took folic acid, iron
46 supplements, or DHA did not influence NAb positivity or IgG positivity ($P >$
47 0.05). Compared with pregnant women who did not take folic acid, the odds ratios (ORs)
48 for the presence of SARS-CoV-2 NAb and IgG antibody in pregnant women who took
49 folic acid were 0.69 ($P = 0.282$; 95% CI, 0.35-1.35) and 1.31 ($P = 0.456$; 95% CI, 0.64-
50 2.67), respectively. Compared with pregnant women who did not take iron supplements,

51 the ORs for the presence of NAb and IgG antibody in pregnant women who took iron
52 supplements were 1.22 ($P = 0.336$; 95% CI, 0.81-1.84) and 1.01 ($P = 0.956$; 95% CI,
53 0.66-1.54), respectively. Similarly, the ORs for NAb and IgG antibody were 0.74 ($P =$
54 0.125; 95% CI, 0.51-1.08) and 0.97 ($P = 0.881$; 95% CI, 0.66-1.44) in pregnant women
55 who took DHA compared with those who did not.

56 **Conclusions:** Nutritional supplementation with folic acid, iron, or DHA during
57 pregnancy was not associated with antibody levels in pregnant women who received
58 inactivated SARS-CoV-2 vaccines.

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73 **1 Introduction**

74 Since the outbreak of COVID-19, research and development of vaccines and
75 various antiviral drugs to combat COVID-19 and its complications have increased
76 worldwide¹⁻⁴. At present, dozens of COVID-19 vaccines have been approved for use
77 around the world. Because pregnant women have not been included in any clinical trials
78 of COVID-19 vaccines^{5,6}, data on the efficacy and safety of these vaccines for pregnant
79 women are limited. In addition, pregnant women have a significantly higher risk of
80 COVID-19 infection, severe disease, and death due to changes in their immune
81 response during pregnancy⁷⁻⁹. Therefore, it is necessary to understand the risks faced
82 by pregnant women and the associated protective factors.

83 Adequate nutrition is essential to ensure the development, operation, and
84 maintenance of the immune system, and nutritional supplements play an important
85 role¹⁰⁻¹². When malnutrition occurs, the immune response is affected, making the body
86 susceptible to infection, which in turn exacerbates malnutrition. Excessive nutrient
87 intake can adversely affect on all components of the immune system. Therefore, a well-
88 balanced diet that includes plenty of nutrient-rich foods and supplements is necessary
89 to prevent infectious diseases and ensure optimal immune function^{12,13}. Some studies
90 have shown that nutrient supplements are particularly important during pregnancy. For
91 example, folic acid is an indispensable nutrient during pregnancy, crucial in preventing
92 neural tube defects¹⁴. In addition, folic acid supplementation during pregnancy has been
93 found to reduce the risk of preeclampsia and preterm birth¹⁵.

94 Iron supplements are also necessary during pregnancy. Iron is an essential trace

95 element for the human body. It supports hemoglobin synthesis and is used in the
96 formation of iron-containing enzymes. It also constitutes the body's iron storage in the
97 form of ferritin^{16,17}. Iron deficiency anemia is one of the most common complications
98 of pregnancy and a risk factor for excessive bleeding during childbirth, premature birth,
99 and low birth weight^{18,19}. Pregnant women with iron deficiency anemia are more
100 susceptible to SARS-CoV-2 infection.

101 DHA is an important component of brain cell membranes and is essential for fetal
102 brain development. DHA supplementation during pregnancy promotes fetal brain
103 development and plays an important role in increasing fetal intelligence and improving
104 vision^{20,21}. The World Health Organization recommends that pregnant women should
105 supplement with at least 300mg of DHA per day. Because of its immunomodulatory
106 effects, DHA supplementation during pregnancy can also improve the immune health
107 of the fetus.

108 Nutritional status during pregnancy is crucial. Many nutrients have potent
109 immunomodulatory effects that can modify susceptibility to COVID-19 infection. It is
110 worth exploring whether nutritional supplements can increase the immune response to
111 COVID-19 vaccines. Therefore, the purpose of this study was to investigate the effect
112 of dietary supplements on antibody levels in pregnant women vaccinated with
113 inactivated SARS-CoV-2 vaccine.

114 **2 Materials and Methods**

115 **2.1 Study design and inclusion criteria**

116 This multicenter study was performed in the obstetric clinics of three hospitals in

117 Guangdong Province, China from December 2021 to July 2022. Inclusion criteria
118 included (1) receiving at least one dose of inactivated vaccine before or during
119 pregnancy, (2) being pregnant and having not been infected with COVID-19, and (3)
120 agreeing to participate and providing informed consent. Pregnant women who were
121 infected with COVID-19 after enrollment and were vaccinated with noninactivated
122 COVID-19 vaccines were excluded. A total of 873 pregnant women met the inclusion
123 criteria. The study was approved by the Medical Ethics Review Board of the School of
124 Public Health, Guangdong Pharmaceutical University (IRB 2021-01), and complied
125 with the Declaration of Helsinki guidelines. All participants signed paper informed
126 consent form and minors were excluded from this study.

127 **2.2 Study variable**

128 We developed a survey questionnaire for pregnant women that included questions
129 such as age (stratified by advanced maternal age as defined by the World Health
130 Organization), body mass index(BMI), gravidity and parity, smoking, doses of vaccine
131 taken, adverse events after vaccination, time since vaccination (defined as the time
132 interval between the last dose of vaccine and blood collection), and other general
133 demographic information, vaccination-related information, and information on the
134 types of nutritional supplements used. Vaccination information was collected through
135 the vaccination registration platform.

136 **2.3 Sample collection and analysis**

137 After enrollment, 5 mL of venous blood was collected, centrifuged to separate the
138 serum, and stored in a -80°C freezer. Neutralizing antibody (NAb) levels were

139 determined via a cytopathogenic effect assay. Specifically, serum samples were
140 inactivated at 56°C for 30 min, diluted fourfold, and incubated with an equal volume
141 (50 µL) of live SARS-CoV-2 virus suspension at 36.5°C in 5% CO₂ for 2 h. Vero cells
142 (1.0–2.0 × 10⁵ cells/mL) were then added to the serum–virus suspension in the
143 microplates and incubated in duplicate at 36.5°C in 5% CO₂ for 5 d. Cytopathological
144 effects were observed under the microscope. A NAb titer of <1:8 was considered
145 negative and ≥1:8 was considered positive. SARS-CoV-2 immunoglobulin G (IgG)
146 antibody was detected by chemiluminescence (Bioscience, Chongqing, China). An
147 antibody level of <1.00 signal to cutoff ratio was considered negative, and a level of
148 ≥1.00 was considered positive.

149 **2.4 Statistical analysis**

150 Statistical analysis was performed in IBM SPSS version 25 (SPSS Inc., IBM Corp.,
151 Armonk, NY). We analyzed demographic data, vaccination-related information, and
152 antibody-positive rates of pregnant women according to whether they were taking
153 nutritional supplements. Chi-squared and Fisher tests were used to compare proportions.
154 Mann–Whitney U-test and Kruskal–Wallis test were used for nonnormal data. A
155 logistic regression model was used to analyze the association between nutritional
156 supplements and SARS-CoV-2 antibody positive rate. All *P*-values were two-sided,
157 and differences with *P*-values <0.05 were considered statistically significant.

158

159 **3 Results**

160 **3.1 Demographics of the study population**

161 Of the 873 pregnant women included in the study, 825 (94.5%) took folic acid,
162 165 (18.9%) took iron supplements, and 197 (22.6%) took DHA during pregnancy. All
163 pregnant women received at least one dose of inactivated SARS-CoV-2 vaccine, and
164 the positive rates of serum SARS-CoV-2 NAbs and IgG antibodies were 44.7% and
165 46.4%, respectively. Of the women included in the study 87.9% were <35 years old.
166 Basic demographic characteristics are presented in Tables 1 and 2.

167

168

169

170

171

172

173

174

175

176

177

178

Table 1 Demographic characteristics of the participants stratified by type of nutrient supplements.

Characteristics	Total (N=873)	Folic acid		P	Iron supplements		P	DHA		P
		Take (N=825)	No take (N=48)		Take (N=165)	No take (N=708)		Take (N=197)	No take (N=676)	
Age group, y				0.054			0.270			0.117
<35	768 (87.9)	730 (88.5)	38 (79.2)		141 (85.5)	627 (88.6)		167 (84.8)	601 (88.9)	
≥35	105 (12.1)	95 (11.5)	10 (20.8)		24 (14.5)	81 (11.4)		30 (15.2)	75 (11.1)	
BMI^a				0.118			0.846			0.832
<18.5	168 (19.2)	160 (19.4)	8 (16.7)		30 (18.2)	138 (19.5)		35 (17.8)	133 (19.7)	
18.5-24	533 (61.1)	508 (61.6)	25 (52.1)		104 (63.0)	429 (60.6)		122 (61.9)	411 (60.8)	
24-28	137 (15.7)	128 (15.5)	9 (18.7)		24 (14.5)	113 (16.0)		31 (15.7)	106 (15.7)	
≥28	35 (4.0)	29 (3.5)	6 (12.5)		7 (4.2)	28 (3.9)		9 (4.6)	26 (3.8)	
Gravidity				0.002*			0.923			0.169
1	357 (40.9)	345 (41.8)	12 (25.0)		68 (41.2)	289 (40.8)		85 (43.1)	272 (40.2)	
2	337 (38.6)	320 (38.8)	17 (35.4)		65 (39.4)	272 (38.4)		81 (41.1)	256 (37.9)	
≥3	179 (20.5)	160 (19.4)	19 (39.6)		32 (19.4)	147 (20.8)		31 (15.7)	148 (21.9)	
Birth				0.012*			0.870			0.377
0	423 (48.5)	405 (49.1)	18 (37.5)		77 (46.7)	346 (48.9)		94 (47.7)	329 (48.7)	
1	335 (38.4)	318 (38.5)	17 (35.4)		66 (40.0)	269 (38.0)		82 (41.6)	253 (37.4)	
≥2	115 (13.1)	102 (12.4)	13 (27.1)		22 (13.3)	93 (13.1)		21 (10.7)	94 (13.9)	
Education				0.008*			0.381			0.077
Middle school and below	219 (25.1)	198 (24.0)	21 (43.8)		40 (24.2)	179 (25.3)		39 (19.8)	180 (26.6)	
High school	187 (21.4)	176 (21.3)	11 (22.9)		38 (23.0)	149 (21.0)		43 (21.8)	144 (21.3)	
Junior college	294 (33.7)	286 (34.7)	8 (16.7)		48 (29.1)	246 (34.7)		65 (33.0)	229 (33.9)	
Bachelor and above	173 (19.8)	165 (20.0)	8 (16.7)		39 (23.6)	134 (18.9)		50 (25.4)	123 (18.2)	

181 **Table 1 (Continued)**

Characteristics	Total (N=873)	Folic acid		P	Iron supplements		P	DHA		P
		Take (N=825)	No take (N=48)		Take (N=165)	No take (N=708)		Take (N=197)	No take (N=676)	
Household income per capita, m				0.061			0.847			0.076
<4000	139 (15.9)	129 (15.6)	10 (20.8)		23 (13.9)	116 (16.4)		23 (11.7)	116 (17.2)	
4000~6000	269 (30.8)	248 (30.1)	21 (43.8)		50 (30.3)	219 (30.9)		57 (28.9)	212 (31.4)	
6000~10000	298 (34.1)	285 (34.5)	13 (27.1)		58 (35.2)	240 (33.9)		69 (35.0)	229 (33.9)	
≥10000	167 (19.2)	163 (19.8)	4 (8.3)		34 (20.6)	133 (18.8)		48 (24.4)	119 (17.6)	
Smoking				0.067			0.008*			0.017*
No	865 (99.1)	819 (99.3)	46 (95.8)		160 (97.0)	705 (99.6)		192 (97.5)	673 (99.6)	
Yes	8 (0.9)	6 (0.7)	2 (4.2)		5 (3.0)	3 (0.4)		5 (2.5)	3 (0.4)	
Number of exercises per week				0.999			<0.001*			0.021*
0	330 (37.8)	312 (37.8)	18 (37.5)		39 (23.6)	291 (41.1)		59 (29.9)	271 (40.1)	
<3	55 (6.3)	52 (6.3)	3 (6.3)		9 (5.5)	46 (6.5)		11 (5.6)	44 (6.5)	
≥3	488 (55.9)	461 (55.9)	27 (56.3)		117 (70.9)	371 (52.4)		127 (64.5)	361 (53.4)	

182 ^a: Since the simple with BMI≥28 was small, it was combined with the simple with 24≤BMI<28 for statistical analysis.

183 *: P < 0.05

Table 2 Vaccination and SARS-CoV-2 antibody positivity rates stratified by type of nutrient supplements.

Characteristics	Total (N=873)	Folic acid		<i>P</i>	Iron supplements		<i>P</i>	DHA		<i>P</i>
		Take (N=825)	No take (N=48)		Take (N=165)	No take (N=708)		Take (N=197)	No take (N=676)	
Doses of vaccination				0.901			<0.001*			<0.001*
One dose	84 (9.6)	79 (9.6)	5 (10.4)		41 (24.8)	43 (6.1)		30 (15.2)	54 (8.0)	
Two doses	669 (76.7)	633 (76.7)	36 (75.0)		114 (69.1)	555 (78.4)		154 (78.2)	515 (76.2)	
Three doses	120 (13.7)	113 (13.7)	7 (14.6)		10 (6.1)	110 (15.5)		13 (6.6)	107 (15.8)	
Adverse events				0.207			0.621			0.825
No	477 (54.6)	455 (55.2)	22 (45.8)		93 (56.4)	384 (54.2)		109 (55.3)	368 (54.4)	
Yes	396 (45.4)	370 (44.8)	26 (54.2)		72 (43.6)	324 (45.8)		88 (44.7)	308 (45.6)	
Inoculation durations, wk				0.096			<0.001*			0.001*
<20	119 (13.6)	109 (13.2)	10 (20.8)		5 (3.0)	114 (16.1)		8 (4.1)	111 (16.4)	
20-24	107 (12.3)	98 (11.9)	9 (18.8)		10 (6.1)	97 (13.7)		22 (11.2)	85 (12.6)	
24-28	202 (23.1)	188 (22.8)	14 (29.2)		30 (18.2)	172 (24.3)		50 (25.4)	152 (22.5)	
28-32	230 (26.3)	221 (26.8)	9 (18.8)		53 (32.1)	177 (25.0)		61 (31.0)	169 (25.0)	
32-36	138 (15.8)	133 (16.1)	5 (10.4)		48 (29.1)	90 (12.7)		38 (19.3)	100 (14.8)	
≥36	77 (8.9)	76 (9.2)	1 (2.1)		19 (11.5)	58 (8.2)		18 (9.1)	59 (8.7)	
Neutralizing Antibody				0.288			0.017*			<0.001*
+	390 (44.7)	365 (44.2)	25 (52.1)		60 (36.4)	330 (46.6)		66 (33.5)	324 (47.9)	
-	483 (55.3)	460 (55.8)	23 (47.9)		105 (63.6)	378 (53.4)		131 (66.5)	352 (52.1)	
SARS-CoV-2 IgG				0.706			<0.001*			0.012*
+	405 (46.4)	384 (46.5)	21 (43.8)		56 (33.9)	349 (49.3)		76 (38.6)	329 (48.7)	
-	468 (53.6)	441 (53.5)	27 (56.3)		109 (66.1)	359 (50.7)		121 (61.4)	347 (51.3)	

186 We found significant differences in gravidity ($P = 0.002$), parity ($P = 0.012$), and
187 education ($P = 0.008$) according to whether the pregnant women took folic acid. The
188 percentage of pregnant women taking folic acid was higher in those with fewer than
189 two pregnancies (80.6%), ≤ 1 birth (87.6%), and junior college education (34.7%).
190 There were statistically significant differences in smoking ($P = 0.008$), weekly exercise
191 frequency ($P < 0.001$), vaccine doses ($P < 0.001$), time since vaccination ($P < 0.001$),
192 SARS-CoV-2 neutralizing antibody ($P = 0.017$), and IgG antibody ($P < 0.001$)
193 according to whether participants were taking iron supplements. The presence or
194 absence of DHA supplementation was similar to the presence or absence of iron
195 supplementation. There were significant differences between groups in smoking ($P =$
196 0.017), weekly exercise frequency ($P = 0.021$), vaccine doses ($P < 0.001$), time since
197 vaccination ($P = 0.001$), SARS-CoV-2 neutralizing antibody ($P < 0.001$), and IgG
198 antibody ($P = 0.012$). There were no statistically significant differences in age, body
199 mass index, per capita monthly income, or adverse events.

200 We further analyzed the general demographic characteristics of the pregnant
201 women taking the three nutritional supplements separately. For pregnant women who
202 took folic acid, the positive rate of SARS-CoV-2 neutralizing antibody varied
203 significantly with vaccine doses ($P < 0.001$) and time since vaccination ($P < 0.001$).
204 The positive rate of IgG antibody varied significantly with age ($P = 0.025$), adverse
205 events ($P = 0.027$), vaccine doses ($P < 0.001$), and time since vaccination ($P < 0.001$).
206 Among pregnant women who took iron, the positive rates of neutralizing antibody and
207 IgG antibody varied significantly with vaccine doses ($P < 0.001$). In pregnant women

208 taking DHA, the difference in the positive rate of IgG antibody between the groups
209 varied significantly with gravidity ($P = 0.040$), vaccine doses ($P < 0.001$), and time
210 since vaccination ($P < 0.001$).The positive rate of NAbs varied significantly with
211 vaccine doses ($P < 0.001$) and time since vaccination ($P = 0.009$) (see Tables 3–5).

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230 **Table 3 Demographic characteristics of the participants taking folic acid.**

Characteristics	Total (N=825)	Neutralizing Antibody		P	IgG		P
		+	-		+	-	
		(N=365)	(N=460)		(N=384)	(N=441)	
Age group, y				0.185			0.025*
<35	730 (88.5)	329 (90.1)	401 (87.2)		350 (91.1)	380 (86.2)	
≥35	95 (11.5)	36 (9.9)	59 (12.8)		34 (8.9)	61 (13.8)	
BMI^a				0.983			0.419
<18.5	160 (19.4)	70 (19.2)	90 (19.6)		68 (17.7)	92 (20.9)	
18.5-24	508 (61.6)	226 (61.9)	282 (61.3)		245 (63.8)	263 (59.6)	
24-28	128 (15.5)	51 (14.0)	77 (16.7)		55 (14.3)	73 (16.6)	
≥28	29 (3.5)	18 (4.9)	11 (2.4)		16 (4.2)	13 (2.9)	
Gravidity				0.734			0.411
1	345 (41.8)	158 (43.3)	187 (40.7)		170 (44.3)	175 (39.7)	
2	320 (38.8)	137 (37.5)	183 (39.8)		143 (37.2)	177 (40.1)	
≥3	160 (19.4)	70 (19.2)	90 (19.6)		71 (18.5)	89 (20.2)	
Birth				0.920			0.572
0	405 (49.1)	182 (49.9)	223 (48.5)		196 (51.0)	209 (47.4)	
1	318 (38.5)	139 (38.1)	179 (38.9)		143 (37.2)	175 (39.7)	
≥2	102 (12.4)	44 (12.1)	58 (12.6)		45 (11.7)	57 (12.9)	
Education				0.829			0.909
Middle school and below	198 (24.0)	86 (23.6)	112 (24.3)		91 (23.7)	107 (24.3)	
High school	176 (21.3)	83 (22.7)	93 (20.2)		86 (22.4)	90 (20.4)	
Junior college	286 (34.7)	126 (34.5)	160 (34.8)		130 (33.9)	156 (35.4)	
Bachelor and above	165 (20.0)	70 (19.2)	95 (20.7)		77 (20.1)	88 (20.0)	
Household income per capita, m				0.097			0.266
<4000	129 (15.6)	57 (15.6)	72 (15.7)		65 (16.9)	64 (14.5)	
4000~6000	248 (30.1)	111 (30.4)	137 (29.8)		119 (31.0)	129 (29.3)	
6000~10000	285 (34.5)	138 (37.8)	147 (32.0)		135 (35.2)	150 (34.0)	
≥10000	163 (19.8)	59 (16.2)	104 (22.6)		65 (16.9)	98 (22.2)	
Smoking				1.000			1.000
No	819 (99.3)	362 (99.2)	457 (99.3)		381 (99.2)	438 (99.3)	
Yes	6 (0.7)	3 (0.8)	3 (0.7)		3 (0.8)	3 (0.7)	
Number of exercises per week				0.285			0.652
0	312 (37.8)	149 (40.8)	163 (35.4)		151 (39.3)	161 (36.5)	
<3	52 (6.3)	22 (6.0)	30 (6.5)		25 (6.5)	27 (6.1)	
≥3	461 (55.9)	194 (53.2)	267 (58.0)		208 (54.2)	253 (57.4)	
Adverse events				0.111			0.027*
No	455 (55.2)	190 (52.1)	265 (57.6)		196 (51.0)	259 (58.7)	
Yes	370 (44.8)	175 (47.9)	195 (42.4)		188 (49.0)	182 (41.3)	

232 **Table 3 (Continued)**

Characteristics	Total (N=825)	Neutralizing Antibody		<i>P</i>	IgG		<i>P</i>
		+	-		+	-	
		(N=365)	(N=460)		(N=384)	(N=441)	
Doses of vaccination				<0.001*			<0.001*
One dose	79 (9.6)	5 (1.4)	74 (16.1)		5 (1.3)	74 (16.8)	
Two doses	633 (76.7)	248 (67.9)	385 (83.7)		266 (69.3)	367 (83.2)	
Three doses	113 (13.7)	112 (30.7)	1 (0.2)		113 (29.4)	0 (0.0)	
Inoculation durations, wk				<0.001*			<0.001*
<20	109 (13.2)	88 (24.1)	21 (4.6)		97 (25.3)	12 (2.7)	
20-24	98 (11.9)	47 (12.9)	51 (11.1)		53 (13.8)	45 (10.2)	
24-28	188 (22.8)	86 (23.6)	102 (22.2)		84 (21.9)	104 (23.6)	
28-32	221 (26.8)	73 (20.0)	148 (32.2)		83 (21.6)	138 (31.3)	
32-36	133 (16.1)	44 (12.1)	89 (19.3)		44 (11.5)	89 (20.2)	
≥36	76 (9.2)	27 (7.4)	49 (10.7)		23 (6.0)	53 (12.0)	

233 *: $P < 0.05$

234 **Table 4 Demographic characteristics of the participants taking iron supplements.**

Characteristics	Total (N=165)	Neutralizing Antibody		P	IgG		P
		+	-		+	-	
		(N=60)	(N=105)		(N=56)	(N=109)	
Age group, y				0.900			0.593
<35	141 (85.5)	51 (85.0)	90 (85.7)		49 (87.5)	92 (84.4)	
≥35	24 (14.5)	9 (15.0)	15 (14.3)		7 (12.5)	17 (15.6)	
BMI^a				0.096			0.300
<18.5	30 (18.2)	6 (10.0)	24 (22.9)		7 (12.5)	23 (21.1)	
18.5-24	104 (63.0)	40 (66.7)	64 (61.0)		36 (64.3)	68 (62.4)	
24-28	24 (14.5)	11 (18.3)	13 (12.4)		11 (19.6)	13 (11.9)	
≥28	7 (4.3)	3 (5.0)	4 (3.8)		2 (3.6)	5 (4.6)	
Gravidity				0.665			0.628
1	68 (41.2)	26 (43.3)	42 (40.0)		23 (41.1)	45 (41.3)	
2	65 (39.4)	21 (35.0)	44 (41.9)		20 (35.7)	45 (41.3)	
≥3	32 (19.4)	13 (21.7)	19 (18.1)		13 (23.2)	19 (17.4)	
Birth				0.489			0.966
0	77 (46.7)	29 (48.3)	48 (45.7)		26 (46.4)	51 (46.8)	
1	66 (40.0)	21 (35.0)	45 (42.9)		22 (39.3)	44 (40.4)	
≥2	22 (13.3)	10 (16.7)	12 (11.4)		8 (14.3)	14 (12.8)	
Education				0.537			0.723
Middle school and below	40 (24.2)	16 (26.7)	24 (22.9)		15 (26.8)	25 (22.9)	
High school	38 (23.0)	10 (16.7)	28 (26.7)		10 (17.9)	28 (25.7)	
Junior college	48 (29.1)	19 (31.7)	29 (27.6)		17 (30.4)	31 (28.4)	
Bachelor and above	39 (23.6)	15 (25.0)	24 (22.9)		14 (25.0)	25 (22.9)	
Household income per capita, m				0.181			0.363
<4000	23 (13.9)	6 (10.0)	17 (16.2)		5 (8.9)	18 (16.5)	
4000~6000	50 (30.3)	14 (23.3)	36 (34.3)		16 (28.6)	34 (31.2)	
6000~10000	58 (35.2)	24 (40.0)	34 (32.4)		20 (35.7)	38 (34.9)	
≥10000	34 (20.6)	16 (26.7)	18 (17.1)		15 (26.8)	19 (17.4)	
Smoking				0.355			0.211
No	160 (97.0)	57 (95.0)	103 (98.1)		53 (94.6)	107 (98.2)	
Yes	5 (3.0)	3 (5.0)	2 (1.9)		3 (5.4)	2 (1.8)	
Number of exercises per week				0.918			0.514
0	39 (23.6)	13 (21.7)	26 (24.8)		11 (19.6)	28 (25.7)	
<3	9 (5.5)	3 (5.0)	6 (5.7)		2 (3.6)	7 (6.4)	
≥3	117 (70.9)	44 (73.3)	73 (69.5)		43 (76.8)	74 (67.9)	
Adverse events				0.358			0.604
No	93 (56.4)	31 (51.7)	62 (59.0)		30 (53.6)	63 (57.8)	
Yes	72 (43.6)	29 (48.3)	43 (41.0)		26 (46.4)	46 (42.2)	

236 **Table 4 (Continued)**

Characteristics	Total (N=165)	Neutralizing Antibody		<i>P</i>	IgG		<i>P</i>
		+	-		+	-	
		(N=60)	(N=105)		(N=56)	(N=109)	
Doses of vaccination				<0.001*			<0.001*
One dose	41 (24.8)	3 (5.0)	38 (36.2)		2 (3.6)	39 (35.8)	
Two doses	114 (69.1)	47 (78.3)	67 (63.8)		44 (78.6)	70 (64.2)	
Three doses	10 (6.1)	10 (16.7)	0 (0.0)		10 (17.9)	0 (0.0)	
Inoculation durations, wk				0.063			0.208
<20	5 (3.0)	4 (6.7)	1 (1.0)		4 (7.1)	1 (0.9)	
20-24	10 (6.1)	3 (5.0)	7 (6.7)		5 (8.9)	5 (4.6)	
24-28	30 (18.2)	15 (25.0)	15 (14.3)		11 (19.6)	19 (17.4)	
28-32	53 (32.1)	14 (23.3)	39 (37.1)		14 (25.0)	39 (35.8)	
32-36	48 (29.1)	15 (25.0)	33 (31.4)		16 (28.6)	32 (29.4)	
≥36	19 (11.5)	9 (15.0)	10 (9.5)		6 (10.7)	13 (11.9)	

237 *: *P* < 0.05

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264 **Table 5 Demographic characteristics of the participants taking DHA.**

Characteristics	Total (N=197)	Neutralizing Antibody		P	IgG		P
		+	-		+	-	
		(N=66)	(N=131)		(N=76)	(N=121)	
Age group, y				0.690			0.294
<35	167 (84.8)	55 (83.3)	112 (85.5)		67 (88.2)	100 (82.6)	
≥35	30 (15.2)	11 (16.7)	19 (14.5)		9 (11.8)	21 (17.4)	
BMI^a				0.826			0.975
<18.5	35 (17.8)	11 (16.7)	24 (18.3)		14 (18.4)	21 (17.4)	
18.5-24	122 (61.9)	40 (60.6)	82 (62.6)		47 (61.8)	75 (62.0)	
24-28	31 (15.7)	11 (16.7)	20 (15.3)		11 (14.4)	20 (16.6)	
≥28	9 (4.6)	4 (6.0)	5 (3.8)		4 (5.3)	5 (4.1)	
Gravidity				0.461			0.040*
1	85 (43.1)	29 (43.9)	56 (42.7)		35 (46.1)	50 (41.3)	
2	81 (41.1)	24 (36.4)	57 (43.5)		24 (31.6)	57 (47.1)	
≥3	31 (15.7)	13 (19.7)	18 (13.7)		17 (22.4)	14 (11.6)	
Birth				0.620			0.231
0	94 (47.7)	31 (47.0)	63 (48.1)		38 (50.0)	56 (46.3)	
1	82 (41.6)	26 (39.4)	56 (42.7)		27 (35.5)	55 (45.5)	
≥2	21 (10.7)	9 (13.6)	12 (9.2)		11 (14.5)	10 (8.3)	
Education				0.786			0.734
Middle school and below	39 (19.8)	13 (19.7)	26 (19.8)		15 (19.7)	24 (19.8)	
High school	43 (21.8)	12 (18.2)	31 (23.7)		14 (18.4)	29 (24.0)	
Junior college	65 (33.0)	22 (33.3)	43 (32.8)		25 (32.9)	40 (33.1)	
Bachelor and above	50 (25.4)	19 (28.8)	31 (23.7)		22 (28.9)	28 (23.1)	
Household income per capita, m				0.582			0.696
<4000	23 (11.7)	6 (9.1)	17 (13.0)		11 (14.5)	12 (9.9)	
4000~6000	57 (28.9)	19 (28.8)	38 (29.0)		20 (26.3)	37 (30.6)	
6000~10000	69 (35.0)	27 (40.9)	42 (32.1)		28 (36.8)	41 (33.9)	
≥10000	48 (24.4)	14 (21.1)	34 (26.0)		17 (22.4)	31 (25.6)	
Smoking				1.000			1.000
No	192 (97.5)	64 (97.0)	128 (97.7)		74 (97.4)	118 (97.5)	
Yes	5 (2.5)	2 (3.0)	3 (2.3)		2 (2.6)	3 (2.5)	
Number of exercises per week				0.710			0.312
0	59 (29.9)	19 (28.8)	40 (30.5)		19 (25.0)	40 (33.1)	
<3	11 (5.6)	5 (7.6)	6 (4.6)		6 (7.9)	5 (4.1)	
≥3	127 (64.5)	42 (63.6)	85 (64.9)		51 (67.1)	76 (62.8)	
Adverse events				0.875			0.988
No	109 (55.3)	36 (54.5)	73 (55.7)		42 (55.3)	67 (55.4)	
Yes	88 (44.7)	30 (45.5)	58 (44.3)		34 (44.7)	54 (44.6)	

265

266 **Table 5 (Continued)**

Characteristics	Total (N=197)	Neutralizing Antibody		<i>P</i>	IgG		<i>P</i>
		+	-		+	-	
		(N=66)	(N=131)		(N=76)	(N=121)	
Doses of vaccination				<0.001*			<0.001*
One dose	30 (15.2)	2 (3.0)	28 (21.4)		3 (3.9)	27 (22.3)	
Two doses	154 (78.2)	51 (77.3)	103 (78.6)		60 (78.9)	94 (77.7)	
Three doses	13 (6.6)	13 (19.7)	0 (0.0)		13 (17.1)	0 (0.0)	
Inoculation durations, wk				0.009*			<0.001*
<20	8 (4.1)	3 (4.5)	5 (3.8)		7 (9.2)	1 (0.8)	
20-24	22 (11.2)	13 (19.7)	9 (6.9)		14 (18.4)	8 (6.6)	
24-28	50 (25.4)	22 (33.3)	28 (21.4)		25 (32.9)	25 (20.7)	
28-32	61 (31.0)	12 (18.2)	49 (37.4)		14 (18.4)	47 (38.8)	
32-36	38 (19.3)	10 (15.2)	28 (21.4)		12 (15.8)	26 (21.5)	
≥36	18 (9.1)	6 (9.1)	12 (9.2)		4 (5.3)	14 (11.6)	

267 *: *P* < 0.05

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282 3.2 Effects of nutritional supplements on antibody levels

283 To determine the effect of nutritional supplements on antibody levels, multivariate
284 logistic regression analysis was performed. After adjustment for confounding factors
285 such as age, education, vaccine doses, and time since vaccination, we found that there
286 was no significant difference in the positive rates of SARS-CoV-2 neutralizing
287 antibody and IgG antibody according to whether participants took the three nutritional
288 supplements ($P > 0.05$). Compared with pregnant women who did not take folic acid,
289 the odds ratios (ORs) for the presence of SARS-CoV-2 NAb and IgG antibody in
290 pregnant women who took folic acid were 0.69 ($P = 0.282$; 95% CI, 0.35-1.35) and
291 1.31 ($P = 0.456$; 95% CI, 0.64-2.67), respectively. Compared with pregnant women
292 who did not take iron supplements, the ORs for the presence of NAb and IgG antibody
293 in pregnant women who took iron supplements were 1.22 ($P = 0.336$; 95% CI, 0.81-
294 1.84) and 1.01 ($P = 0.956$; 95% CI, 0.66-1.54), respectively. Similarly, the ORs for
295 NAb and IgG antibody were 0.74 ($P = 0.125$; 95% CI, 0.51-1.08) and 0.97 ($P = 0.881$;
296 95% CI, 0.66-1.44) in pregnant women who took DHA compared with those who did
297 not (Table 6).

298

299

300

301

302

303

304 **Table 6 Multivariable logistic regression analysis of Nutritional supplements and antibody**
 305 **positivity.**

Characteristics	<i>P</i>	Neutralizing Antibody OR (95%CI)	<i>P</i>	IgG OR (95%CI)
Folic acid				
No take		1.00		1.00
Take	0.282	0.69 (0.35-1.35)	0.456	1.31 (0.64-2.67)
Chalybeate				
No take		1.00		1.00
Take	0.336	1.22 (0.81-1.84)	0.956	1.01 (0.66-1.54)
DHA				
No take		1.00		1.00
Take	0.125	0.74 (0.51-1.08)	0.881	0.97 (0.66-1.41)

306 Adjusted for age, BMI, education, number of exercises per week, adverse events, inoculation
 307 durations, doses of vaccination.

308

309

310 **4 Discussion**

311 The present study showed no association between supplementation during
 312 pregnancy and antibody levels in pregnant women who received inactivated SARS-
 313 CoV-2 vaccines.

314 During the COVID-19 pandemic, vaccination has proven to be the most effective
 315 control measure in establishing an immune barrier and reducing the rate of severe
 316 disease. Although pregnant women were not included in the clinical trials of COVID-
 317 19 vaccines before market release, they face higher severity and mortality rates once
 318 infected. Therefore, there is a greater need for pregnant women to get vaccinated in
 319 order to protect themselves and their fetuses. With more attention paid to pregnant
 320 women's health and nutrient intake, nutritional supplements have been ubiquitously
 321 used during pregnancy. Because the development and maintenance of immune cells

322 that support vaccine response depend on a sufficient supply of nutrients, the role of
323 nutritional supplements in immune response to vaccines has drawn increasing attention.

324 Clinical studies show that low plasma DHA levels during fetal development are
325 associated with cognitive and behavioral disorders²². The brain needs DHA
326 supplementation during development of the nervous system. DHA supplementation
327 during pregnancy can increase fetal birth weight, reduce the risk of preterm birth and
328 low birth weight, and also have a positive effect on infant attention regulation^{23,24}. Thus
329 it is necessary to pay attention to DHA intake during pregnancy. In a double-blind,
330 placebo-controlled, randomized trial, children of mothers who took DHA supplements
331 during pregnancy were found to have better problem-solving abilities at age 9 y than
332 those who did not²⁵. Taking DHA supplements also improves the health of pregnant
333 women. A randomized controlled trial of low-income African American women
334 showed that pregnant women who received DHA supplementation reported lower
335 levels of stress and had lower levels of stress hormones²⁶. The results of this research
336 indicate that DHA intake is not associated with pregnant women's antibody levels.

337 Folic acid is essential for DNA and protein synthesis and also plays a crucial role
338 in adaptive immune responses²⁷. Pregnancy is a common cause of folic acid deficiency,
339 which can lead to pregnancy complications and affect the growth and development of
340 children, including pregnancy-induced hypertension, increased risk of miscarriage,
341 neural tube defects, cleft lip and palate. Studies have shown that folic acid
342 supplementation during pregnancy may help reduce the risk of prenatal depression and
343 have beneficial effects on fertility^{28,29}. The Centers for Disease Control and Prevention

344 in the USA recommends that women of childbearing age supplement with 400 µg/d of
345 folic acid daily, beginning at least four weeks before conception and continuing through
346 the first three months of pregnancy. In terms of vaccine immune response, taking folic
347 acid during pregnancy increases the persistence of hepatitis B surface antibodies in the
348 fetus³⁰. Our study showed that taking folic acid is not associated with pregnant women's
349 antibody levels. This is because the aforementioned study explored the relationship
350 between folic acid supplements during pregnancy and the immune persistence of
351 antibodies in the fetus, which differs from the focus of our research. Other confounding
352 factors in this study, such as vaccine dosage and income level, may also contribute to
353 this result. In a cluster randomized clinical trial conducted in Niger, the effect of
354 prenatal nutritional supplements on immune responses to oral attenuated rotavirus
355 vaccine was assessed. The results showed that in this low-income country, the types of
356 prenatal nutritional supplements have no effect on immune reactions³¹.

357 Iron, an essential nutrient, plays a significant role in the immune system³². Every
358 cell and organ system in the human body requires iron for normal development and
359 metabolic function. Iron deficiency often causes anemia during pregnancy, severely
360 threatening the health of pregnant women and fetuses and increasing the incidence of
361 adverse pregnancy outcomes. A meta-analysis showed a dose-response relationship
362 between iron and birth weight, where before reaching a dose of 66mg, every additional
363 10mg/day of iron supplementation can increase birth weight by 15.1g, reduce the risk
364 of low birth weight by 3%, and decrease the rate of anemia by 12%³³. In a birth cohort
365 study, anemia and iron deficiency during babies' vaccination were found to predict a

366 decrease in response to vaccines against diphtheria, whooping cough, and
367 pneumococcus. Iron supplementation increases antibody affinity and seroconversion of
368 the measles vaccine³⁴. Our study showed that taking iron supplements does not affect
369 antibody levels in pregnant women. This may be because the efficacies of various
370 vaccines differ across populations, age groups, and environmental conditions.

371 Iron, folic acid and DHA are important nutrient supplements during pregnancy. A
372 cross-sectional study conducted in China found that the use rate of folic acid was the
373 highest (81.7%) and the most stable among various nutrient supplements³⁵. Women of
374 childbearing age and pregnant women are at risk of developing anemia, and iron
375 deficiency is the most recognized risk factor for this condition. Pregnancy poses a
376 significant risk of iron deficiency for women. Iron requirements are greatly increased
377 compared to the non-pregnant state. Adequate iron during pregnancy leads to better
378 pregnancy outcomes for both mother and child. During pregnancy, DHA is transferred
379 in large quantities to the fetus through the placenta. The maternal DHA nutritional
380 status directly affects the fetal DHA nutritional status, which in turn affects fetal
381 development.

382 This research is a cross-sectional study based on real-world data, differing from
383 the aforementioned studies in terms of research design. Furthermore, differences in
384 research subjects and vaccines can also cause different results. For example, the
385 mechanisms of vaccines may vary between the immune systems of fetuses and pregnant
386 women, thereby producing inconsistent immune responses. Finally, readjusting an
387 established immune system may require additional intervention beyond nutritional

388 supplements, and the most effective supplement has not been identified.

389 We acknowledge some limitations in present study. Because the data on
390 supplements taken by pregnant women were based on self-report, there may have been
391 some recall bias. Another drawback is the lack of survey information on nutrient intake
392 among pregnant women, which could lead to imprecise results. In the future, we may
393 consider measuring the baseline levels of nutritional supplements in the first trimester
394 and evaluating the effects of nutrient supplements such as vitamin D, calcium, and zinc
395 on the immune levels of pregnant women, to provide more effective recommendations
396 on nutrient intake for pregnant women.

397

398 **5 Conclusions**

399 Nutritional supplementation with folic acid, iron, and DHA during pregnancy was
400 not associated with antibody levels in pregnant women who received inactivated
401 SARS-CoV-2 vaccines.

402 **Acknowledgments**

403 We thank all pregnant women who took part in this survey and the health care
404 workers who helped us.

405

406 **References**

407 [1] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China Medical
408 Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590
409 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* (2020)
410 May 14;55(5):2000547. doi: 10.1183/13993003.00547-2020.

- 411 [2] Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, et al.
412 Women's views on accepting COVID-19 vaccination during and after pregnancy,
413 and for their babies: a multi-methods study in the UK. *BMC Pregnancy Childbirth*.
414 (2022) Jan 14;22(1):33. doi: 10.1186/s12884-021-04321-3.
- 415 [3] Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients
416 with immune-mediated inflammatory disease: Review of available evidence. *J Am*
417 *Acad Dermatol.*(2021)Nov;85(5):1274-1284.doi: 10.1016/j.jaad.2021.07.054.
- 418 [4] Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-
419 19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and
420 escape. *Nat Rev Immunol.* (2021) Oct;21(10):626-636. doi: 10.1038/s41577-021-
421 00592-1.
- 422 [5] Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, et al.
423 COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients,
424 and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview
425 of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine
426 Efficacy and Safety. *Drug Saf.* (2021) Dec;44(12):1247-1269.
427 doi:10.1007/s40264-021-01131-6.
- 428 [6] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
429 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* (2021) Feb
430 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
- 431 [7] Gorun F, Motoi S, Malita D, Navolan DB, Nemescu D, Olariu TR, et al.
432 Cytomegalovirus seroprevalence in pregnant women in the western region of
433 Romania: A large-scale study. *Exp Ther Med.* (2020) Sep;20(3):2439-2443. doi:
434 10.3892/etm.2020.8945.
- 435 [8] Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal
436 and Neonatal Morbidity and Mortality Among Pregnant Women With and
437 Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study.
438 *JAMA Pediatr.* (2021) Aug 1;175(8):817-826. doi:
439 10.1001/jamapediatrics.2021.1050. Erratum in: *JAMA Pediatr.* 2022 Jan

- 440 1;176(1):104.
- 441 [9] Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al.
442 Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2
443 Infection in Pregnant Women. *JAMA*. (2021) Aug 24;326(8):728-735. doi:
444 10.1001/jama.2021.11035.
- 445 [10] Maggini S, Pierre A, Calder PC. Immune Function and Micronutrient
446 Requirements Change over the Life Course. *Nutrients*. (2018) Oct 17;10(10):1531.
447 doi: 10.3390/nu10101531.
- 448 [11] Junaid K, Ejaz H, Abdalla AE, Abosalif KOA, Ullah MI, Yasmeen H, et al.
449 Effective Immune Functions of Micronutrients against SARS-CoV-2. *Nutrients*.
450 (2020) Sep 29;12(10):2992. doi: 10.3390/nu12102992.
- 451 [12] Iddir M, Brito A, Dingo G, Fernandez Del Campo SS, Samouda H, La Frano MR,
452 Bohn T. Strengthening the Immune System and Reducing Inflammation and
453 Oxidative Stress through Diet and Nutrition: Considerations during the COVID-
454 19Crisis. *Nutrients*. (2020) May27;12(6):1562. doi: 10.3390/nu12061562.
- 455 [13] Samartin S., Chandra R. Obesity, overnutrition and the immune system. *Nutr. Res*.
456 (2001);21:243–262. doi: 10.1016/S0271-5317(00)00255-4.
- 457 [14] Brown B, Wright C. Safety and efficacy of supplements in pregnancy. *Nutr Rev*.
458 (2020) Oct 1;78(10):813-826. doi: 10.1093/nutrit/nuz101.
- 459 [15] Bulloch RE, Lovell AL, Jordan VMB, et al. Maternal folic acid supplementation
460 for the prevention of preeclampsia: a systematic review and meta-
461 analysis. *Paediatr Perinat Epidemiol*. (2018);32:346–357.
- 462 [16] Zamora TG, Guiang SF 3rd, Widness JA, Georgieff MK. Iron is prioritized to red
463 blood cells over the brain in phlebotomized anemic newborn lambs. *Pediatr Res*.
464 (2016) Jun;79(6):922-8. doi: 10.1038/pr.2016.20.
- 465 [17] Petry N, Olofin I, Hurrell RF, Boy E, Wirth JP, Moursi M, et al. The Proportion
466 of Anemia Associated with Iron Deficiency in Low, Medium, and High Human
467 Development Index Countries: A Systematic Analysis of National Surveys.
468 *Nutrients*. (2016) Nov 2;8(11):693. doi: 10.3390/nu8110693.

- 469 [18] Figueiredo ACMG, Gomes-Filho IS, Silva RB, Pereira PPS, Mata FAFD, Lyrio
470 AO, et al. Maternal Anemia and Low Birth Weight: A Systematic Review and
471 Meta-Analysis. *Nutrients*. (2018) May 12;10(5):601. doi: 10.3390/nu10050601.
- 472 [19] Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, et al. Maternal
473 anemia and risk of adverse birth and health outcomes in low- and middle-income
474 countries: systematic review and meta-analysis. *Am J Clin Nutr*.
475 (2016)Feb;103(2):495-504. doi: 10.3945/ajcn.115.107896.
- 476 [20] Shulkin M, Pimpin L, Bellinger D, Kranz S, Fawzi W, Duggan C, et al. n-3 Fatty
477 Acid Supplementation in Mothers, Preterm Infants, and Term Infants and
478 Childhood Psychomotor and Visual Development: A Systematic Review and
479 Meta-Analysis. *J Nutr*. (2018) Mar 1;148(3):409-418. doi: 10.1093/jn/nxx031.
- 480 [21] Larqué E, Gil-Sánchez A, Prieto-Sánchez MT, Koletzko B. Omega 3 fatty acids,
481 gestation and pregnancy outcomes. *Br J Nutr*. (2012) Jun;107 Suppl 2:S77-84. doi:
482 10.1017/S0007114512001481.
- 483 [22] Jouanne M, Oddoux S, Noël A, Voisin-Chiret AS. Nutrient Requirements during
484 Pregnancy and Lactation. *Nutrients*. (2021) Feb 21;13(2):692. doi:
485 10.3390/nu13020692.
- 486 [23] Vinding RK, Stokholm J, Sevelsted A, Chawes BL, Bønnelykke K, Barman M, et
487 al. Fish Oil Supplementation in Pregnancy Increases Gestational Age, Size for
488 Gestational Age, and Birth Weight in Infants: A Randomized Controlled Trial. *J*
489 *Nutr*. (2019) Apr 1;149(4):628-634. doi: 10.1093/jn/nxy204.
- 490 [24] Colombo J, Gustafson KM, Gajewski BJ, Shaddy DJ, Kerling EH, Thodosoff JM,
491 et al. Prenatal DHA supplementation and infant attention. *Pediatr Res*. (2016)
492 Nov;80(5):656-662. doi: 10.1038/pr.2016.134.
- 493 [25] Judge MP, Harel O, Lammi-Keefe CJ. Maternal consumption of a
494 docosahexaenoic acid-containing functional food during pregnancy: benefit for
495 infant performance on problem-solving but not on recognition memory tasks at
496 age 9 mo. *Am J Clin Nutr*. (2007) Jun;85(6):1572-7. doi: 10.1093/ajcn/85.6.1572.
- 497 [26] Keenan K, Hipwell AE, Bortner J, Hoffmann A, McAloon R. Association between

- 498 fatty acid supplementation and prenatal stress in African Americans: a randomized
499 controlled trial. *Obstet Gynecol.* (2014) Dec;124(6):1080-1087. doi:
500 10.1097/AOG.0000000000000559.
- 501 [27] Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, et al. Role of vitamins
502 and minerals as immunity boosters in COVID-19. *Inflammopharmacology.* (2021)
503 Aug;29(4):1001-1016. doi: 10.1007/s10787-021-00826-7.
- 504 [28] Jin X, Cheng Z, Yu X, Tao Q, Huang R, Wang S. Continuous supplementation of
505 folic acid in pregnancy and the risk of perinatal depression-A meta-analysis. *J*
506 *Affect Disord.* (2022) Apr 1;302:258-272. doi: 10.1016/j.jad.2022.01.
- 507 [29] Gaskins AJ, Chavarro JE. Diet and fertility: a review. *Am J Obstet Gynecol.* (2018)
508 Apr;218(4):379-389. doi: 10.1016/j.ajog.2017.08.010.
- 509 [30] Zhao X, Pang X, Wang F, Cui F, Wang L, Zhang W. Maternal folic acid
510 supplementation and antibody persistence 5 years after hepatitis B vaccination
511 among infants. *Hum Vaccin Immunother.* (2018);14(10):2478-2484. doi:
512 10.1080/21645515.2018.1482168.
- 513 [31] Sanaka S, Garba S, Plikaytis B, Malone McNeal M, Guindo O, Langendorf C, et
514 al. Immunogenicity of an oral rotavirus vaccine administered with prenatal
515 nutritional support in Niger: A cluster randomized clinical trial. *PLoS Med.* (2021)
516 Aug 10;18(8):e1003720. doi: 10.1371/journal.pmed.
- 517 [32] Kehl-Fie TE, Skaar EP. Nutritional immunity beyond iron: a role for manganese
518 and zinc. *Curr Opin Chem Biol.* (2010) Apr;14(2):218-24. doi:
519 10.1016/j.cbpa.2009.11.008.
- 520 [33] Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Nutrition
521 Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of
522 adverse pregnancy outcomes: systematic review and meta-analysis. *BMJ.* (2013)
523 Jun 21;346:f3443. doi: 10.1136/bmj.f3443.
- 524 [34] Toffel NU, Uyoga MA, Mutuku FM, Frost JN, Mwasi E, Paganini D, et al. Iron
525 Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response
526 and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine

527 Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in
528 Kenyan Infants. *Front Immunol.* (2020) Jul 13;11:1313. doi:
529 10.3389/fimmu.2020.01313.

530 [35] Chatterjee R, Shand A, Nassar N, Walls M, Khambalia AZ. Iron supplement use
531 in pregnancy - Are the right women taking the right amount? *Clin Nutr.* (2016)
532 Jun;35(3):741-7. doi: 10.1016/j.clnu.2015.05.014.

533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551